Wedbush Issues a Downgrade for Cerus (NASDAQ:CERS) from a Outperform to Neutral Rating


Cerus (NASDAQ:CERS) Receives a Downgrade

In analysts report issued to investors and clients on Thursday, 17 December, stock analysts at Wedbush’s equity division lowered the rating for Cerus (NASDAQ:CERS) shares from the previous Outperform to a Neutral.

Approximately 1.23M shares of stock traded hands or 38.34% up from the average. Cerus Corporation (NASDAQ:CERS) has risen 41.72% since May 14, 2015 and is uptrending. It has outperformed by 43.98% the S&P500.

The overall sentiment of institutions has increased to 1.33 in Q2 2015. Its up 0.31, from 1.02 in 2015Q2. The ratio increased, as 14 institutions have sold all the shares of Cerus Corporation that they owned while 32 funds have taken shares off the table. 19 funds have purchased shares for the first time while 42 added to their positions. These institutions now hold 73.42 million shares or 11.23% more than the 66.01 million shares they owned in 2015Q2.

The Fund Lesa Sroufe & Co currently is holding shares equating to 2.14% of its total portfolio in Cerus Corporation representing a total of 592,092 shares. Another fund,Salzhauer Michael, is holding a total of 286,880 shares equating to 1.07% of their holdings. Additionally, Elk Creek Partners Llc has a 2.85 million share stake in Cerus Corporation which represents 1.05% of their total portfolio. The Fund, Rail, based out of Alabama, has also built up a stake in the stock, which represents a total of 0.88% of their total portfolio. Finally Baker Bros. Advisors Lp, a fund which is based in the state of New York reported a total holdings of 13.55 million shares.

Cerus Corporation is a biomedical products firm engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The company has a market cap of $620.23 million. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. It currently has negative earnings. The Firm has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells.

According to Zacks Investment Research, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.”